Methods and compositions for treating degenerative bone...

Details Methods and compositions for treating degenerative bone... Methods and compositions for treating degenerative bone...

2006-06-13

2009-08-18

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S102000, C514S256000, C514S492000

Reexamination Certificate

active

07576053

ABSTRACT:
The present disclosure provides methods and compositions using Syk inhibitory compounds for treating degenerative bone disorders and as prophylactic treatment to prevent bone loss. These treatments may reduce the fracture risk associated with bone loss and compromised bone strength.

REFERENCES:
patent: 4866048 (1989-09-01), Calverley et al.
patent: 5194431 (1993-03-01), Deluca et al.
patent: 5206229 (1993-04-01), Calverley et al.
patent: 5292728 (1994-03-01), Neef et al.
patent: 5446035 (1995-08-01), Neef et al.
patent: 5532228 (1996-07-01), Neef et al.
patent: 6242434 (2001-06-01), Bishop et al.
patent: 6284730 (2001-09-01), Dietrich et al.
patent: 6534524 (2003-03-01), Kania et al.
patent: 6573295 (2003-06-01), Shakespeare et al.
patent: 6762179 (2004-07-01), Cochran et al.
patent: 6835722 (2004-12-01), Kang et al.
patent: 6849641 (2005-02-01), Tang et al.
patent: 6897207 (2005-05-01), Cox et al.
patent: 6897208 (2005-05-01), Edwards et al.
patent: 7060827 (2006-06-01), Singh et al.
patent: 7122542 (2006-10-01), Singh et al.
patent: 7329671 (2008-02-01), Singh et al.
patent: 7329672 (2008-02-01), Singh et al.
patent: 7332484 (2008-02-01), Singh et al.
patent: 2004/0029902 (2004-02-01), Singh et al.
patent: 2004/0106615 (2004-06-01), Cochran et al.
patent: 2004/0142947 (2004-07-01), Cox et al.
patent: 2004/0198750 (2004-10-01), Green et al.
patent: 2004/0214817 (2004-10-01), Pierce et al.
patent: 2005/0004152 (2005-01-01), Cochran et al.
patent: 2005/0009876 (2005-01-01), Bhagwat et al.
patent: 2005/0113398 (2005-05-01), Argede et al.
patent: 2005/0209230 (2005-09-01), Singh et al.
patent: 2005/0234049 (2005-10-01), Singh et al.
patent: 2006/0035891 (2006-02-01), Li et al.
patent: 2006/0058525 (2006-03-01), Singh et al.
patent: 2006/0135543 (2006-06-01), Singh et al.
patent: 2006/0167254 (2006-07-01), Cooper et al.
patent: 2006/0211657 (2006-09-01), Singh et al.
patent: 2006/0234983 (2006-10-01), Singh et al.
patent: 2006/0270694 (2006-11-01), Wong
patent: 2006/0293311 (2006-12-01), Li et al.
patent: 2007/0060603 (2007-03-01), Singh et al.
patent: 2007/0117775 (2007-05-01), Payan
patent: 2007/0167439 (2007-07-01), Singh et al.
patent: 2007/0197782 (2007-08-01), Clough et al.
patent: 2007/0203161 (2007-08-01), Argade et al.
patent: 2007/0203162 (2007-08-01), Li et al.
patent: 2007/0225321 (2007-09-01), Singh et al.
patent: 2007/0225495 (2007-09-01), Singh et al.
patent: 2007/0293520 (2007-12-01), Singh et al.
patent: 2007/0293521 (2007-12-01), Singh et al.
patent: 2007/0293522 (2007-12-01), Singh et al.
patent: 2007/0293523 (2007-12-01), Singh et al.
patent: 2007/0293524 (2007-12-01), Singh et al.
patent: 2007/0299095 (2007-12-01), Singh et al.
patent: WO 99/47529 (1999-09-01), None
patent: WO 00/27802 (2000-05-01), None
patent: WO 02/096905 (2002-12-01), None
patent: WO 03/000688 (2003-01-01), None
patent: WO 03/000695 (2003-01-01), None
patent: WO 03/020698 (2003-03-01), None
patent: WO 2004/014382 (2004-02-01), None
patent: WO 2004/016597 (2004-02-01), None
patent: WO 2004/046120 (2004-06-01), None
patent: WO 2004/085388 (2004-10-01), None
patent: WO 2004/092154 (2004-10-01), None
patent: WO 2005/013982 (2005-02-01), None
patent: WO 2005/027848 (2005-03-01), None
patent: WO 2006/078846 (2006-07-01), None
PCT International Search Report from PCT/US2006/023070 dated Dec. 12, 2006.
U.S. Appl. No. 11/539,074, filed Oct. 5, 2006, Singh et al.
U.S. Appl. No. 11/539,142, filed Oct. 5, 2006, Singh et al.
U.S. Appl. No. 11/782,581, filed Jul. 24, 2007, Singh et al.
U.S. Appl. No. 11/875,772, filed Oct. 19, 2007, Li et al.
U.S. Appl. No. 11/943,506, filed Nov. 20, 2007, Bhamidipati et al.
U.S. Appl. No. 12/028,581, filed Feb. 8, 2008, Argade et al.
U.S. Appl. No. 12/030,031, filed Feb. 12, 2008, Li et al.
U.S. Appl. No. 12/030,069, filed Feb. 12, 2008, Argade et al.
U.S. Appl. No. 12/053,382, filed Mar. 21, 2008, Atuegbu et al.
U.S. Appl. No. 12/053,438, filed Mar. 21, 2008, Li et al.
U.S. Appl. No. 12/175,441, filed Jun. 17, 2008, Singh et al.
Atkins et al. 2003, “Rankl expression is related to the differentiation state of human osteoblasts”J. Bone Miner, Res.18(6):1088-1098.
Boutry et al. 2003, “Trabecular bone structure of the calcaneus: preliminary in vivo MR imaging assessment in men with osteoporsis”Radiology227(3):708-717.
Clemens et al. 1997, “Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption”Clin. Chem.43(11):2058-2063.
Corral et al. 1998, “Dissociation between bone resorption and bone formation in osteopenic transgenic mice”Proc. Natl. Acad. Sci. USA95(23):13835-13840.
Dempster et al. 2001 “Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study”J. Bone Miner. Res.16(10):1846-1853.
Denoto et al. 1981, “Human growth hormone DNA sequence and mRNA structure: possible alternative splicing”Nucleic Acids Res.9(15):3719-3730.
Fox et al. 1998, “A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase”Protein Science7(11):2249-2255.
Garnero et al. 2001, “Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis”Clin. Chem.47(4):694-702.
Ghiron et al. 1995, “Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women”J. Bone Miner. Res.10(12):1844-1852.
Halleen et al. 1999, “Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase”J. Biol. Chem.274(33):22907-22910.
Halleen et al. 2001, “Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption”Clin. Chem.47(3):597:-600.
Henrotin et al. 2001, “Strontium ranelate increases cartilage matrix formation”J. Bone Miner. Res.16(2):299-308.
Hill et al. 1989, “The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase”Clin. Chim. Acata186(2):315-320.
Janckila et al. 2003, “Disease-specific expression of tartrate-resistant acid phosphatase isoforms”J. Bone Miner. Res.18(10):1916-1919.
Jiang et al. 2000, “Micro CT and Micro MR imaging of 3D architecture of animal skeleton”J. Musculoskelet. Neuronal. Interact.1(1):45-51.
Jiang et al. 2003, “Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure”J. Bone Miner. Res.18(11):1932-1941.
Jilka et al. 1996, “Linkage of decreased bone mass with impaired osteoblastogenesis in murine model of accelerated senescence”J. Clin. Invest.97(7):1732-1740.
Katznelson et al. 1996, “Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism”J. Clin. Endocrin. Metab.81(12):4358-4365.
Kawakami et al. 2003, “A Ras activation pathway dependent on Sky phosphorylation of protein kinase C”Proc. Natl. Acad. Sci. USA100(16):9470-9475.
Lai et al. 2003, “Potent small molecule inhibitors of spleen tyrosine kinase (Syk)”Bioorg. Med. Chem. Lett.13(18):3111-3114.
Lau et al. 2003, “Osteoblastic tartrate-resistant acid phosphatase: its potential role in the molecular mechanism of osteogenic action of fluoride”J. Bone Miner Res.18(10):1897-1900.
Lin et al. 1998, “Heterogeneity of trabecular bone structure in the calcaneus using magnetic resonance imaging”Osteoporos Int.8:16-24.
Lubec et al. 1996, “Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria”Biochim. Biophys. Acta1315(3):159-162.
MacInnis et al. 2003, “Determinants of bone density in 30- to 65-year-old women: a co-twin study”J. Bone Miner. Res.18(9):1650-1656.
Maruyama et al. 1996,

Affiliated with

Also associated with

Rating

Methods and compositions for treating degenerative bone... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treating degenerative bone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating degenerative bone... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4069461